Piperlongumine, a novel treatment option to overcome BRAF inhibitor resistance in melanoma

被引：0
|
作者：
Ramachandran, Sharavan [1 ]
Fofaria, Neel [1 ]
Srivastava, Sanjay [1 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
    Fedorenko, Inna V.
    Paraiso, Kim H. T.
    Smalley, Keiran S. M.
    BIOCHEMICAL PHARMACOLOGY, 2011, 82 (03) : 201 - 209
  • [32] Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
    Lassen, Amanda
    Atefi, Mohammad
    Robert, Lidia
    Wong, Deborah J. L.
    Cerniglia, Michael
    Comin-Anduix, Begonya
    Ribas, Antoni
    MOLECULAR CANCER, 2014, 13
  • [33] Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
    Shi, Hubing
    Hugo, Willy
    Kong, Xiangju
    Hong, Aayoung
    Koya, Richard C.
    Moriceau, Gatien
    Chodon, Thinle
    Guo, Rongqing
    Johnson, Douglas B.
    Dahlman, Kimberly B.
    Kelley, Mark C.
    Kefford, Richard F.
    Chmielowski, Bartosz
    Glaspy, John A.
    Sosman, Jeffrey A.
    van Baren, Nicolas
    Long, Georgina V.
    Ribas, Antoni
    Lo, Roger S.
    CANCER DISCOVERY, 2014, 4 (01) : 80 - 93
  • [34] Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma
    Nickoloff, Brian J.
    Vande Woude, George
    PIGMENT CELL & MELANOMA RESEARCH, 2012, 25 (06) : 758 - 761
  • [35] Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
    Vergani, Elisabetta
    Beretta, Giovanni L.
    Aloisi, Mariachiara
    Costantino, Matteo
    Corno, Cristina
    Frigerio, Simona
    Tinelli, Stella
    Dugo, Matteo
    Accattatis, Felice Maria
    Granata, Agnese
    Arnaboldi, Lorenzo
    Rodolfo, Monica
    Perego, Paola
    Gatti, Laura
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [36] New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma
    Pinto, Rosamaria
    De Summa, Simona
    Garrisi, Vito Michele
    Strippoli, Sabino
    Azzariti, Amalia
    Guida, Gabriella
    Guida, Michele
    Tommasi, Stefania
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [37] Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
    Amanda Lassen
    Mohammad Atefi
    Lidia Robert
    Deborah JL Wong
    Michael Cerniglia
    Begonya Comin-Anduix
    Antoni Ribas
    Molecular Cancer, 13
  • [38] P63 contributes to acquired BRAF inhibitor resistance in melanoma
    Patel, A.
    Harwood, C.
    Bergamaschi, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (05) : E52 - E52
  • [39] BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma
    Li, Ying-Ying
    Wu, Chunjing
    Chen, Shu-Mei
    Wangpaichitr, Medhi
    You, Min
    Spector, Seth
    Feun, Lynn G.
    Kuo, Macus T.
    Savaraj, Niramol
    CANCER RESEARCH, 2014, 74 (19)
  • [40] BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
    Rizos, Helen
    Menzies, Alexander M.
    Pupo, Gulietta M.
    Carlino, Matteo S.
    Fung, Carina
    Hyman, Jessica
    Haydu, Lauren E.
    Mijatov, Branka
    Becker, Therese M.
    Boyd, Suzanah C.
    Howle, Julie
    Saw, Robyn
    Thompson, John F.
    Kefford, Richard F.
    Scolyer, Richard A.
    Long, Georgina V.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1965 - 1977
12345